Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 31.41% | 52.03% | 42.47% | -13.10% | -207.84% |
| Total Depreciation and Amortization | -37.32% | -41.92% | -44.78% | -39.79% | -37.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.22% | -87.74% | -87.76% | -60.70% | -52.77% |
| Change in Net Operating Assets | 105.18% | 97.64% | -58.66% | 10.95% | -2.12% |
| Cash from Operations | 41.83% | 26.43% | -62.43% | -182.26% | -1,354.28% |
| Capital Expenditure | 99.65% | 99.62% | -7,258.01% | -4,069.39% | -3,331.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.43% | -87.34% | 167.44% | 204.31% | 77.88% |
| Cash from Investing | 201.39% | -81.44% | 56.81% | 172.10% | -15.46% |
| Total Debt Issued | 190.86% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 519.93% | 91.23% | 65.12% | -40.47% | -66.21% |
| Repurchase of Common Stock | -374.00% | -88.40% | -71.23% | 7.11% | 40.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 195.37% | 73,758.91% | 54,888.68% | 5,054.35% | 2,401.10% |
| Foreign Exchange rate Adjustments | 684.73% | 345.21% | 33.02% | 1,221.74% | -424.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 253.47% | 261.59% | 343.84% | 90.63% | -296.57% |